Business
Novo Nordisk to present new Wegovy® (semaglutide 2.4 mg) data at the 2025 American Association for the Study of Liver Diseases annual meeting
Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, The Liver Meeting® 2025, from 7 to 11 November in Washington D.C., U.S. Highlights include clinical and real-world data investigating the clinical profile of Wegovy® (semaglutide 2.4 mg) in metabolic dysfunction-associated steatohepatitis (MASH) in relation to weight loss and across diverse patient populations. In addition to semaglutide 2.4 mg data
About this update from Novo Nordisk A/s Class B
[{"type":"list","items":[{"val":[{"type":"text","content":"11 new abstracts including MASH data to be presented at the 76th Annual AASLD The Liver Meeting®, 7-11 November","length":111,"tagName":"p"}]},{"val":[{"type":"text","content":"Highlights include data from post-hoc analyses of the ESSENCE trial investigating the effects of Wegovy® (semaglutide 2.4 mg) in MASH in relation to the magnitude of weight loss and across diverse populations1,2","length":216,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":327,"olType":false},{"type":"text","content":"BAGSVÆRD, Denmark and PLAINSBORO, N.J., Oct. 28, 2025 /PRNewswire/ -- Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, The Liver Meeting® 2025, from 7 to 11 November in Washington D.C., U.S. Highlights include clinical and real-world data investigating the clinical profile of Wegovy® (semaglutide 2.4 mg) in metabolic dysfunction-associated steatohepatitis (MASH) in relation to weight loss and across diverse patient populations. In addition to semaglutide 2.4 mg data, real-world data will be presented that evaluate the benefit of non-invasive tests (NITs).","length":666,"tagName":"p"},{"type":"text","content":""The breadth and depth of our clinical trial program illustrates our abiding commitment to improve health outcomes for patients with serious chronic diseases, including MASH," said Martin Holst Lange, chief scientific officer and executive vice president, Research & Development at Novo Nordisk. "These post-hoc analyses of the ESSENCE trial help to provide insight into clinical effects of semaglutide 2.4 mg across different stages of MASH disease progression, as well as within diverse population subgroups."","length":535,"tagName":"p"},{"type":"text","content":"The research to be presented at The Liver Meeting® 2025 reflects Novo Nordisk's leadership in advancing the understanding of optimal screening, diagnosis, and management of MASH and other serious chronic conditions.","length":219,"tagName":"p"},{"type":"text","content":"Summary of presentationsAccepted data at The Liver Meeting® 2025 include the following poster and oral presentations. Accepted abstracts include preliminary data that may be subject to change in the final published manuscripts. Dates ...